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Abstract 
Introduction: 
The estimated global prevalence of diabetes mellitus for adults aged 20-70 in 2015 was 415 million 
with approximately 90% of diagnosed cases being Type 2 diabetes mellitus (T2DM). Improvements 
in lifestyle and effective therapies are key to management but due to the progressive nature of 
T2DM, pharmacotherapy is typically required. Whilst the initial therapy will usually be with 
metformin, thereafter treatment should be individualised, with consideration of several different 
second line options. These include the dipeptidyl peptidase-4 (DPP-4) inhibitors, of which 
omarigliptin is the second once weekly version.  
 
Areas covered: 
The paper summarises key pharmoacodynamic and pharmacokinetic features and reviews the 
efficacy and safety trial data of omarigliptin, a once-weekly DPP-4 inhibitor. 
 
Expert opinion: 
Omarigliptin results in a significant improvement in glycaemia with an effective once weekly 
pharmacokinetic profile and low risk of drug-drug interactions. It has equivalent efficacy to existing 
once daily DPP-4 inhibitors and shares a similar side effect profile. It is weight neutral with a 
significantly lower risk of hypoglycaemia compared with sulphonylureas. Adherence to prescribed 
medication is poor in patients with T2DM. Once weekly omarigliptin is a welcomed addition to the 
therapeutic armoury but whether it will improve compliance remains to be seen. 
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1 Introduction 
In 2006 the United Nations recognised diabetes as a global epidemic, the first non-infectious 
disease to be acknowledged as posing a worldwide health threat (1). The estimated global 
prevalence for adults aged 20-70 in 2015 was 415 million and this is expected to rise to 642 million 
by 2040 (2). Type 2 diabetes (T2DM) is responsible for approximately 90% of the diagnosed cases 
although a significant number of people with T2DM, approximately 1 in 2 (46%), remain 
undiagnosed (3). It is more common in deprived communities (75% of adults with T2DM live in 
low or middle income countries) and 5 million people die from diabetes-related illness each year 
(3). In the UK it’s estimated to account for 10% of total NHS spend, largely due to the long-term 
complications caused by diabetes. Good glycaemic control reduces the risk of complications (4, 5, 
6), particularly microvascular ones such as kidney disease and visual loss.  
 
A healthy lifestyle is the cornerstone of T2DM management. Diet and exercise modifications are 
usually followed by or combined with pharmacological therapy. Metformin is the initial treatment 
of choice (7, 8) in the majority of indivduals with T2DM. If the combination of metformin and 
healthy lifestyle fails to control glycaemia, additional glucose lowering medication is added. 
Traditionally the next step was a sulphonylurea due to its efficacy, low cost acquisition and 
availability. However as a result of glucose-lowering studies such as ACCORD (9) and ADVANCE 
(10), current guidelines (7, 8) recognise that treatment should be tailored to the individual. The 
result of this is that many different therapeutic options can and should be considered as possible 2
nd
 
line treatments. These include thiazolidinediones (7, 8), glucagon-like peptide-1 receptor agonists 
(GLP-1 RA) (8), sodium-glucose cotransporter 2 (SGLT2) inhibitors (7), DPP-4 inhibitors (7, 8) 
and insulin (8). Failure to achieve adequate control at this point would typically lead to triple 
therapy using combinations of the above medications.  
 
T2DM occurs as a consequence of insulin resistance, and inadequate insulin secretion. Under 
normal circumstances nutrients in the small intestine and raised blood glucose levels lead to the 
release of incretin peptides, Glucagon-like peptide-1 (GLP-1) and Gastrointestinal peptide (GIP) 
into the circulation. These peptides cause a glucose-dependent release of insulin by activating G-
protein coupled receptors on the surface of pancreatic β cells whilst GLP-1 also reduces hepatic 
glucose production by inhibiting glucagon secretion from islet α cells. The incretin peptides have a 
short plasma half life (1-2 minutes) as they undergo rapid enzymatic degradation by DPP-4.  T2DM 
is associated with a significant reduction in GLP-1 production and intravenous infusion of GLP-1 
restores normoglycaemia (11); hence elevation of endogenous GLP-1 levels by inhibiting it’s 
destruction was seen as a therapeutic target. Inhibition of DPP-4 using oral DPP-4 inhibitors, leads 
to an increased concentration of endogenous GLP-1 and GIP resulting in significant improvements 
in glycaemic control, and appears to have a greater efficacy in Asians than Caucasians (12). In 
addition, since insulin release induced by DPP-4 inhibitors is glucose-dependent, it is associated 
with significantly fewer episodes of hypoglycaemia than traditional therapy with sulphonylureas. 
 
Eleven DPP-4 inhibitors have now been approved for use in man. There are seven once daily DPP-4 
inhibitors: alopgliptin, evogliptin, gemigliptin, linagliptin, saxagliptin, sitagliptin, and teneligliptin; 
two twice daily anagliptin and vildagliptin; and two once weekly trelagliptin and omarigliptin (13). 
Whilst these have different characteristics based on their unique chemical structures, clinical trials 
have failed to demonstrate a significant difference in efficacy. HbA1c reductions of 0.6-0.8% are 
typically recorded compared to placebo at the end of 12-24 week trials. Generally they are well 
tolerated, with low rates of hypoglycaemia unless added to insulin or insulin secretagogues (such as 
sulphonylureas), and are weight neutral, unlike sulphonylureas, insulin and thiazolidinediones 
which lead to weight gain.   
 
 
2 Body of Review 
2.1. Overview of the market 
Type 2 diabetes is a chronic, lifelong condition which exposes sufferers to an increased risk of 
vascular complications. The complications can be divided broadly into macrovascular 
(cerebrovascular, cardiovascular and peripheral vascular disease) and microvascular (retinopathy, 
nephropathy and neuropathy). In addition to not smoking, key elements of management include 
control of blood pressure, lipids and glucose levels. As a result individuals with type 2 diabetes are 
often required to take multiple drug therapies in an attempt to control these risk factors but 
compliance has been shown to be poor (14). The development of once weekly products may 
simplify complex daily regimens and aid compliance.  
 
Until March 2015 the only DPP-4 inhibitors available on the market were once or twice daily 
products. Since then two new once weekly gliptins have been approved in Japan (13), trelagliptin 
(March 2015) and omarigliptin (September 2015). Whether once weekly gliptin preparations will 
improve compliance and as a consequence glycaemic control remains to be seen but they are a 
welcome addition to the market. 
 
2.2. Introduction to the compound 
Omarigliptin is a once weekly dipetidyl peptidase-4 (DPP-4) inhibitor. Produced by Merck & Co. 
Inc., it received regulatory authority in Japan in September 2015 for monotherapy, or dual and triple 
therapy with other oral hypoglycaemics (15). It is generally prescribed at a dose of 25mg once 
weekly. There is no required dose reduction in mild or moderate renal impairment, but it needs to 
be reduced to 12.5mg once weekly in severe renal impairment (eGFR <30mls/minute/1.73m
2
). 
There are no dose restrictions with any degree of hepatic impairment (16).  
 
 
2.3. Chemistry 
The molecular formula of omarigliptin (MK-1032) is C17H20F2N4O3S, (Box 1), with a molecular 
weight of 394.4 g/mol. 
 
Omarigliptin is created by a reductive amination of tetrahydropyranone with 
methylsulfonylpyrrolopyrazole in the presence of triacetoxyborohydride in dimethylacetal. The 
intermediates produced by this are then subject to deprotection and neutralisation with ammonium 
hydroxide, and crystallisation from ethyl acetate to form omarigliptin (17). 
  
2.4. Pharmacodynamics 
Omarigliptin exhibits dose-dependent DPP-4 inhibition (17). Trough DPP-4 activity is inhibited by 
approximately 90%, leading to a 2-fold postprandial increase in mean active GLP-1 and a 
significant postprandial glucose reduction compared with placebo (18). In line with other DPP-4 
inhibitors it is well tolerated, weight neutral and has a low incidence of symptomatic 
hypoglycaemia (19).  
 
2.5. Pharmacokinetics and metabolism 
Omarigliptin is a reversible competitive inhibitor of DPP-4, which is more potent than sitagliptin 
the current market leader (IC50 omarigliptin 1.6nM, sitagliptin 18nM) (17). The pharmacokinetic 
profile of omarigliptin is biphasic with a long terminal half-life of >100 hours which allows for a 
once weekly dosing regimen. It is rapidly absorbed, the AUC and Cmax of omarigliptin is 
proportional to the dose used, reaching a steady state within 2-3 weeks. (17, 18). There is minimal 
accumulation after multiple dosing, which suggests that omarigliptin reaches therapeutic levels with 
the first dose (18).  
  
The pharmacokinetic profile of omarigliptin has been shown to be the same in obese individuals 
with and without T2DM (18). It does not require restrictions based on an individuals demographics 
nor the timing of meals since food, age, gender, obesity and race do not appear to have a significant 
effect on its pharmacokinetic profile. 
 
Omarigliptin is eliminated largely unchanged in the urine (74.4%) having undergone minimal 
metabolism. A small amount (3.4%) has also been recovered from faeces. Whilst several minor 
metabolites have been found in the urine no active metabolites have been identified to date. Its 
excretion does not appear to be meaningfully altered by mild or moderate renal impairment and as a 
result no dose adjustment is required. Individuals with significant renal impairment, and end stage 
renal disease requiring haemodialysis however, experience a 1.6 and 2 fold increase in AUC 
respectively (20). A 50% dose reduction (omarigliptin 12.5mg once weekly) is recommended in this 
situation. 
 
 
2.6 Clinical efficacy 
 
2.6.1. Glycaemia 
Phase I 
Administration of omarigliptin in single and multiple doses in two phase I double blind, 
randomised, placebo controlled studies of healthy volunteers led to a 2 fold rise in mean active 
GLP-1 concentrations in keeping with its mechanism of action as a DPP-4 inhibitor (21). A similar 
increase in mean active GLP-1 was seen in response to 50mg omarigliptin in obese individuals with 
and without diabetes, as well as a significant reduction in post-meal glucose of 0.7 mmol/L 
compared to placebo (18). Omarigliptin was associated with a non-significant reduction in weight 
which is consistent with the weight neutral effect of other DPP-4 inhibitors (22). 
 Phase II 
In a 12 week phase II, double-blind, randomised, dose ranging study assessing the effect of 
omarigliptin 0.25mg, 1mg, 3mg, 10mg or 25mg once weekly against placebo in individuals with 
T2DM the greatest improvement in glycaemic control was seen with the 25mg dose of omarigliptin 
(19). There was a significant (p<0.001) improvement in HbA1c -0.72% (-0.93, -0.5), 2 hour post 
meal glucose -2.5 mmol/L (-3.3, -1.7), and fasting plasma glucose -1.3 mmol/L at 12 weeks. 
Similarly a greater proportion of individuals on omarigliptin 25mg once weekly achieved the 
HbA1c target <7.0% (33.6% v 21.8%), or <6.5% (13.6% v 4.5%) compared with placebo.  
 
Subjects completing the baseline study (18) were eligible to join a 66 week extension study (Table 
1). All individuals in the omarigliptin arm, including those initially on 25mg, were given 
omarigliptin 25mg once weekly whilst the placebo arm were initially treated with blinded 
pioglitazone and later metformin. At the end of the 66 week extension the percentage of individuals 
achieving an HbA1c target of <7.0% and <6.5% increased with increasing omarigliptin dose, but 
there was no significant difference in HbA1c target attainment between the placebo/metformin arm 
(45.8% & 29.2% respectively) and those who had initially been given and continued to receive 
omarigliptin 25 mg in the extension study (43.5% & 21.7% respectively). There was a gradual 
deterioration in glycaemic control for all treatment groups towards the end of the extension study, 
which appeared similar to that observed with other glucose lowering treatments (5, 6). Weight 
neutrality was observed in both the baseline and extension study. 
 
 
 
 
 
Phase III 
The clinical development programme for omarigliptin O-QWEST (Omarigliptin Q Weekly Efficacy 
and Safety in Type 2 Diabetes) involves 10 Phase III clinical trial and approximately 8000 patients 
with T2DM.  
 
In a 24 week, phase III, head to head study in subjects with T2DM (Table 1) inadequately 
controlled on metformin, omarigliptin 25mg once weekly achieved its primary endpoint and was 
non-inferior to sitagliptin 100mg once daily at reducing HbA1C levels from baseline (omarigliptin -
0.47%; sitagliptin -0.43% (difference -0.03% [95% CI -0.15 to 0.08])). In addition, a similar 
number of patients achieved an HbA1C <6.5% (omarigliptin 27%; sitagliptin 23% (p=0.212)) (23).  
 
A 54 week, head-to-head, phase III trial in people with T2DM (Table 1) inadequately controlled 
with metformin comparing add on therapy with omarigliptin 25mg once weekly to glimperide 
titrated as required up to a maximum of 6mg once daily, failed to demonstrate any significant 
difference in HbA1c (omarigliptin -0.30% (-0.39 to – 0.21) v glimepiride -0.48% (-0.57 to -0.39))  
or fasting plasma glucose (omarigliptin -0.15mmol/L (-0.37 to 0.07) v glimepiride -0.46 mmol/L (-
0.69 to -0.24)) between the two arms. Numerically, fewer subjects attained an HbA1c target <7.0% 
(omarigliptin 47.7% (42.3 to 53.1) v glimepiride 58% (52.7 to 63.1)) or <6.5% (omarigliptin 25.1% 
(20.6 to 30.2) v glimepiride 28.8% (24.1 to 34.0)) on omarigliptin than with glimperide. There was, 
however, a significant increase in the number of participants experiencing symptomatic 
hypoglycaemia with glimepiride compared with omarigliptin (26.7% v 5.3% (p<0.001)) and in 
weight compared to baseline (1.5kg (1.1 to 1.9) v -0.4 Kg (-0.8 to 0.0) (p<0.001)) (24). 
 
In a recently completed phase III, multicenter, randomized, double-blind, placebo-controlled trial 
(Table 1) the addition of omarigliptin 25mg once weekly to individuals with T2DM inadequately 
controlled on a combination of metfomin and glimepiride (triple therapy) significantly reduced 
HbA1c by -0.67% (-0.84 to -0.50) compared with placebo -0.06% (-0.23 to 0.12) (p<0.001) (25). 
The omarigliptin arm also achieved its secondary endpoint targets of a significant reduction in 
fasting plasma glucose compared to placebo (-1.1 v -0.2 mmol/L (p<0.001)) and a significantly 
higher percentage attained HbA1c target of <7.0% (23.8% v 4.4% (p<0.001)) and <6.5% (10.1% v 
2.1% (p<0.01)). 
 
 
2.6.2. Ongoing trials of interest: 
Phase III trials designed to assess the safety and efficacy of omarigliptin in young adults (26), and 
those with increasingly severe renal impairment including established haemodialysis (27) have 
recently completed and results are awaited.  
 
2.7. Safety and Tolerability 
The adverse events in phase I and II studies have tended to be mild and transient. The most 
frequently reported adverse events attributed to omarigliptin were headaches, dizziness, and nausea  
(17, 28). There have been no consistent abnormalities in the history, physical examination, 
laboratory safety tests (lipids (TC, HDL, LDL & Tg), liver function, creatinine kinase, creatinine 
and eGFR) or ECG studies, including a detailed QTc study (29).  
 
Omarigliptin is largely renally excreted. Phase I studies have identified the need to reduce the dose 
from 25mg to 12.5mg once weekly in presence of severe renal impairment (eGFR 
<30mls/minute/1.73m
2
) or end stage renal disease but no adjustment is required with hepatic 
impairment (16). 
 
Adverse event data in Phase III trials appears to be consistent with safety data from Phase I and II 
trials. In a recent phase III study comparing omarigliptin 25mg once weekly against sitagliptin 
100mg OD a similar number experienced serious (omarigliptin 11 (3.4%) verses sitagliptin 9 
(2.8%)) or drug related (omarigliptin 123 (3.7%) verses sitagliptin 12 (3.8%)) adverse events, and 
there was no significant difference in the number who discontinued (omarigliptin 3 (0.9%) verses 
sitagliptin 7 (2.2%) 95% CI -3.6 to 0.8) in both study arms. Symptomatic and asymptomatic 
hypoglycaemia was recorded in 3.7% of the omarigliptin group (one severe) compared with 4.7% of 
the sitagliptin group, whilst the commonest recorded adverse events were diarrhoea, influenza, 
urinary tract infection, lipase increase and back pain (Table 2).  
 
A randomized, double-blind, placebo-controlled study assessing cardiovascular outcomes following 
treatment with omarigliptin in 4000 subjects with T2DM has recently been terminated by Merck as 
it no longer plans to submit a marketing application in the United States or Europe (30). There were 
no additional efficacy or safety concerns reported during this study. 
 
2.7.1. Interactions: 
Omarigliptin does not inhibit cytochrome p450s (CYPIA2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4), phase 
2 enzymes (UGTIA1, SULTIE1) or key drug transporters (human P-gp, BCRP, OATPIB1, 
OATPIB3, hOAT1, hOAT3, hOCT1, hOCT2) nor does it induce CYP1A2, CYP2B6 or CYP3A4. It 
therefore has low risk of drug-drug interactions.  
 
2.7.2. Post-marketing surveillance 
Omarigliptin was launched in Japan during the last quarter of 2015. To date post marketing 
surveillance studies have not been published. 
 
In summary the incidence of hypoglycaemia is low and comparable to placebo. There are currently 
no significant concerns identified to suggest that omariglitpin has a different safety profile to daily 
dosed DPP-4 inhibitors.  
 2.8. Regulatory affairs 
Omarigliptin received regulatory authority in Japan in September 2015 for monotherapy, or dual 
and triple therapy with other oral hypoglycaemics (15). Currently there are no plans to submit 
additional marketing applications. 
 
3 Conclusion 
Omarigliptin is a once weekly DPP-4 inhibitor with equivalent efficacy to once daily preparations. 
The therapeutic effect of DPP-4 inhibitors relates to their effectiveness in inhibiting DPP-4 enzyme 
rather than a direct end-organ effect. Since the DPP-4 inhibitors generally have a similar effect on 
the enzyme they have equivalent efficacy.  
 
The incidence of hypoglycaemia is low and comparable to placebo but in keeping with all DPP-4 
inhibitors will be increased when combined with sulphonylureas or insulin. To date, no significant 
concerns have been identified to suggest that omarigliptin has a different safety profile to daily 
dosed DPP-4 inhibitors. It appears to have a low risk of drug-drug interactions. 
 
Omarigliptin has a licence for mono, dual or triple therapy and is prescribed at a dose of 25mg once 
weekly. There is no required dose reduction in mild or moderate renal impairment, but it needs to 
be reduced to 12.5mg once weekly in severe renal impairment (eGFR <30mls/minute/1.73m
2
). 
There are no dose restrictions with any degree of hepatic impairment (16). 
 
 
4 Expert opinion 
Whilst diet and lifestyle remain the cornerstone of T2DM management there is a need to develop 
safe, efficacious treatments which improve compliance. Omarigliptin is the second once weekly 
DPP-4 inhibitor to be licenced. It results in a significant improvement in glycaemia with an 
effective once weekly pharmacokinetic profile. It has equivalent efficacy to existing once daily 
DPP-4 inhibitors, and shares a similar side effect profile. Omarigliptin is weight neutral with a 
significantly lower risk of hypoglycaemia than sulphonylureas. Deterioration in glycaemic control 
was seen at the end of an 18 month extension study, as seen with other glucose lowering treatments 
which do not appear to impact on the progressive nature of hyperglycaemia in T2DM.  
 
The decision not to licence omarigliptin in the European Union and United States was not made 
because of safety concerns and appears to have been based on marketing considerations. This 
contrasts markedly with the development of GLP-1RAs, where three once weekly preparations are 
currently licenced in western countries and more are being assessed in phase 3 trials. These 
differences probably reflect the therapy algorithms prevalent in different regions and the mode of 
administration of these different incretin classes, as outlined below. 
 
The ADA/EASD position statement (31) for the management of T2DM recommends metformin as 
first-line therapy in all cases (except those for whom it is contraindicated). Metformin, an oral 
preparation, is given on a daily basis often in divided doses so as to improve tolerability. Even the 
extended release versions of metformin are often administered twice daily to reduce side-effects.  
 
ADA/EASD (31) recommends DPP-4 inhibitors as a possible second-line after metformin and so 
the convenience of omarigliptin being a once weekly administration is negated by being on a 
background of multiple daily dosing. Moreover, it is possible that compliance with the currently 
available once daily DPP-4 inhibitors might be better than with a once-weekly version in this 
setting. In the UK and some other countries, economic considerations lead to DPP-4 inhibitors 
being used as third-line agents (after metformin and sulphonylureas or pioglitazone). This further 
dilutes the potential advantage of once weekly omarigliptin. 
 The ADA/EASD position statement (31) also recommends that GLP1-RAs are considered as a 
second-line therapy after metformin although other guidelines (e.g. from the National Institute for 
Health and Care Excellence (32)) position them after failure of triple oral therapy. In any event, 
they are all currently injectable agents and so many patients will prefer less frequent administration. 
In addition, there is emerging evidence that long-acting GLP1-RA therapy may have cardiovascular 
advantages over shorter acting agents. 
 
In Japan, metformin has never achieved the primacy over other anti-diabetes therapies seen in the 
West. Sulphonylureas have headed traditional guidelines and here the DPP-4 inhibitors have made 
major in-roads into the diabetes therapies marketplace. This is due to their advantages of low 
hypoglycaemia and weight neutrality over the sulphonylureas. So, for many clinicians, DPP-4s are 
the first line therapy for T2DM and the option of once weekly omarigliptin versus daily therapies is 
more obvious. It may also represent a more ‘gradual’ introduction of treatment which may be 
attractive for patients. Whether once weekly omarigliptin will improve compliance and, thereby, 
produce better levels of glycaemic control in real-world conditions remains to be seen. 
  
Future research and development in the DPP-4 field is likely to be influenced by results from 
cardiovascular outcome trials (CVOTs) in other classes of anti-diabetes agents. There have now 
been three CVOTs of DPP-4 inhibitors (saxagliptin (33), alogliptin (34) and sitagliptin (35)) which 
confirmed their primary end-point – demonstration of non-inferiority for a composite 
cardiovascular (CV) endpoint versus placebo. However, CVOTs of empagliflozin (36) (an oral 
SGLT2 inhibitor), liraglutide (37) and semaglutide (38) (once daily and once weekly GLP-1RAs 
respectively) not only showed non-inferiority but were also found to be superior with respect to 
their CV endpoint. If these results are confirmed as class effects, generalisable to T2DM patients at 
lower levels of CV risk than those included in the current trials, then it is likely that DPP-4 
inhibitors will move down the treatment algorithms. This will especially be the case if the on-going 
development of an oral GLP-1RA (semaglutide) is successful. In this scenario, further development 
of the largely off-patent DPP-4 class may be limited. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLES 
 
 
Table 1 Efficacy of Omarigliptin in individuals with Type 2 diabetes mellitus 
 
Phase and Type of trial, 
Comparator treatment arms 
HbA1c 
(%) 
FPG 
(mmol/L) 
Achieved 
HbA1c 
<7% 
Achieved 
HbA1c 
<6.5% 
Phase II 
Mono 
Omarigliptin 25mg qw -0.57 (-0.73 to -0.42) 
0.14 (0.01 to 0.3) 
-1 (-1.3 to -0.7) 
0.3 (0.0 to 0.6) 
33.6% 
21.8%  
13.6% 
4.5% Placebo 
Significance (p<0.001) (p<0.001) (NS) (NS) 
Phase III 
Dual 
 
 
Omarigliptin 25mg qw -0.47 -0.8 54.4% 28.8% 
Sitagliptin 100mg OD -0.43 -0.5 52.4% 24.4% 
Significance  (NS) (NS) (NS) (NS) 
Phase III 
Dual 
Omarigliptin 25mg qw -0.3 (-0.39 to -0.21) -0.15 (-0.37 to -0.07) 47.7% 25.1% 
Glimepiride 1-6mg OD -0.48 (-0.57 to -0.39) -0.46 (-0.69 to -0.24) 58.0% 28.8% 
Significance (NS) (NS)  (NS) 
Phase III 
Triple 
Omarigliptin 25mg qw -0.67 (-0.84 to -0.5) -1.1 23.8% 10.1% 
Placebo -0.06% (-0.23 to 0.12) -0.2 4.4% 2.1% 
Significance p<0.001 p<0.001 p<0.001 p<0.001 
 
Dual therapy = Metformin (≥1500mg) plus Omarigliptin verses Sitagliptin or Glimepiride 
Triple therapy = Metformin (≥1500mg), and Glimepiride (≥4mg) plus Omarigliptin or placebo. 
(NS) = Not significant 
 
 
 
 
 
Table 2 Adverse events with incidence ≥2% in one or more treatments in patients with Type 2 
diabetes mellitus in a phase III trial comparing Omarigliptin with Sitagliptin  
 
 Omarigliptin Sitagliptin 
Diarrhoea 0.9% 2.8% 
Influenza 0.3% 2.2% 
Urinary tract infection 1.2% 2.8% 
Lipase increase 2.5% 4.1% 
Back pain 2.5% 0.6% 
Any hypoglycaemia 
(symptomatic or 
asymptomatic) 
 
3.7% 
 
4.7% 
Severe hypoglycaemia 1 event No events 
 
 
 
 
 
 
 BOX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BOX 1 Drug Summary 
 
Drug name   Omarigliptin 
 
Indication   Type 2 diabetes mellitus 
 
Route of administration Oral  
 
Mechanism of action  blockade of dipeptidyl peptidase-4 (DPP-4)  
 
Chemical structure 
 
 
 
 
(Adapted from Biftu T et al. A novel long-acting DPP-4 inhibitor for once-weekly treatment of 
Type 2 diabetes. Journal of Medicinal Chemistry 2014;57:3205-3212) 
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